Catalyst Dossier · compiled by Celia 🧫

UCB (UCBJY)

Healthcare · market cap $53.9B · as of 2026-06-23

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-06-30 (est.)

Phase 3

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

UCB (UCBJY) is a Belgian specialty biopharmaceutical company with approximately 8,600 employees and a market cap of roughly $53.9 billion, focused primarily on neurology and immunology. Its commercial portfolio spans established epilepsy franchises (Levetiracetam, Lacosamide, Brivaracetam), immunology assets (Bimekizumab, Certolizumab Pegol/Cimzia, Zilucoplan, Rozanolixizumab), and CNS/movement disorder programs. The near-term catalyst slate is dense, with multiple Phase 3 readouts across Bimekizumab, Brivaracetam, Zilucoplan, and other assets expected through early 2027.

The catalyst path

2026-06-30 (est.)Phase 3 · Staccato alprazolamimp 9/10
2026-07-28 (est.)Phase 3 · Bimekizumabimp 9/10
2026-08-07 (est.)Phase 3 · Bimekizumabimp 9/10
2026-08-24 (est.)Phase 3 · Brivaracetamimp 9/10
2026-09-01 (est.)Phase 3 · fenfluramineimp 9/10
2026-11-16 (est.)Phase 3 · Zilucoplanimp 9/10
2026-12-21 (est.)Phase 3 · Bimekizumabimp 9/10
2027-02-25 (est.)Phase 3 · Brivaracetamimp 9/10

Pipeline

Asset	Phase	Indication
Antiepileptic drugs with market authorization available per country	Phase 3	Epilepsy
SPM 927	Phase 3	Partial Seizures With or Without Secondary Generalization
Cimzia	Phase 3	Crohn Disease
Etanercept	Phase 3	Psoriasis
Certolizumab Pegol	Phase 3	Rheumatoid Arthritis
Brivaracetam	Phase 3	Epilepsy
Secukinumab	Phase 3	Chronic Plaque Psoriasis
levocetirizine dihydrochloride	Phase 3	Rhinitis
Ketotifen	Phase 3	Rhinitis, Allergic, Perennial
Lacosamide	Phase 3	Epilepsy
Bimekizumab	Phase 3	Chronic Plaque Psoriasis
Rotigotine Nasal Spray	Phase 2	Restless Legs Syndrome
Ustekinumab	Phase 3	Chronic Plaque Psoriasis
UCB0022	Phase 2	Parkinson Disease
Certolizumab Pegol + Methotrexate (MTX)	Phase 3	Rheumatoid Arthritis
Kemstro	Phase 3	Multiple Sclerosis
Rozanolixizumab	Phase 3	Generalized Myasthenia Gravis
UCB7665	Phase 2	Thrombocytopenia
Levocetirizine	Phase 3	Rhinitis, Allergic, Seasonal
SPM927/Lacosamide	Phase 2	Painful Diabetic Neuropathy

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by Celia. The catalyst path & pipeline above are free.

See Pro

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by Celia. Not financial advice.